Varex (VREX) director Bardwell receives 8,483 shares from deferred units

Rhea-AI Filing Summary

Varex Imaging Corp. director Kathleen Bardwell reported the conversion of equity awards into common stock. On February 9, 2026, she converted 8,483 Deferred Stock Units into 8,483 shares of common stock at an exercise price of $0 per share.

The filing shows this equity award delivery increased her directly held common stock to 12,102 shares after the transaction. Each Deferred Stock Unit converts into one share of common stock, reflecting previously granted and vested director compensation rather than an open-market purchase or sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bardwell Kathleen

(Last) (First) (Middle)

C/O VAREX IMAGING CORP.

1678 S. PIONEER ROAD

(Street)

SALT LAKE CITY UT 84104

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Varex Imaging Corp [ VREX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/09/2026		M		8,483	A	(1)	12,102	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Stock Units	(1)	02/09/2026		M			8,483	(2)	(2)	Common Stock	8,483	$0	0	D

Explanation of Responses:

1. Each Deferred Stock Unit converts into common stock on a one-for-one basis.

2. These Deferred Stock Units were issued on February 9, 2023, vested on February 8, 2024, and delivery of the vested Deferred Stock Units, in the form of common stock occurred on February 9, 2026, the third anniversary of the date of grant.

Remarks:

	/s/ Kathleen L. Bardwell	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Varex (VREX) director Kathleen Bardwell report?

Kathleen Bardwell reported an equity award conversion, not a market trade. On February 9, 2026, 8,483 Deferred Stock Units converted into 8,483 shares of Varex common stock at an exercise price of $0 per share as part of her director compensation.

How many Varex (VREX) shares does Kathleen Bardwell hold after this Form 4?

After the reported transaction, Kathleen Bardwell directly holds 12,102 Varex common shares. This total reflects delivery of 8,483 shares from previously granted Deferred Stock Units that vested earlier and were settled in stock on February 9, 2026.

What are Deferred Stock Units in the Varex (VREX) Form 4 filing?

Deferred Stock Units are equity awards that convert into common stock later. For Bardwell, each Deferred Stock Unit converts one-for-one into Varex common shares, delivering 8,483 shares on February 9, 2026 as part of her director compensation package.

Were Bardwell’s Deferred Stock Units in Varex (VREX) newly granted in 2026?

No, the Deferred Stock Units were granted earlier and settled in 2026. They were issued on February 9, 2023, vested on February 8, 2024, and were delivered as 8,483 common shares on February 9, 2026, the third anniversary of the grant.

Did the Varex (VREX) director sell any shares in this Form 4 transaction?

The Form 4 shows a conversion, not a sale. Bardwell exercised 8,483 Deferred Stock Units into 8,483 shares of common stock at $0 per share, increasing her direct holdings to 12,102 shares with no reported market sale in this filing.

Is the Varex (VREX) Form 4 transaction a routine equity compensation event?

Yes, the disclosures describe a routine settlement of director equity awards. Previously issued Deferred Stock Units from 2023 vested in 2024 and were delivered as 8,483 common shares in 2026, consistent with the grant’s three-year anniversary settlement terms.